China's new drug research and development progress in May 2014

1 Chemical 1.1 R & D progress Suzhou Runxin biology applied for rx108, but no relevant information was found Tianjin Xin Chen Tai Fei has reported the bromine amine spray, conjecture that this medicine ibuprofen water soluble prodrug, the patent is CN101489985, may by injecting the mouth or the nasal cavity way to treat the asthma Bgb-283 is a B-Raf inhibitor developed by Baiji Shenzhou In May 2013, bgb-283 transferred its rights abroad to Merck Serono In May 2014, bgb-283 entered phase I clinical practice and obtained the $5 million mileage fee paid by Merck Serono According to the company's May 19 announcement, the indications for the production of p-toluenesulfonamide in HongRi pharmaceutical are central lung cancer with severe airway obstruction The drug can be used as adjuvant therapy by local injection of tumor, and no pharmacological mechanism has been found Viagra is a new antithrombotic drug jointly developed by Jiangsu Weikeli and China Pharmaceutical University Part of the preliminary work was published in Journal of medical chemistry Greys are P2Y12 ADP receptor inhibitors, and clopidogrel, prasugrel and tegrel have been listed Tpn171h is a class 1.1 new drug jointly developed by Shandong tepharman Pharmaceutical (www.topharman Com) and Shen Jingshan research group of Shanghai Institute of medicine It is used to treat male erectile dysfunction and pulmonary hypertension, and entered the second round of 2015 major special review The indication of tpn171 is the same as that of tpn729 I guess tpn171 is also PDE5 inhibitor Ramazolam is a GABA receptor agonist, which is used for surgical anesthesia There is no compound patent Hengrui has a patent for tosylate crystal form (wo2013029431) Last year, it applied for clinical application Renfu changed tosylate into benzene sulfonate The company has three candidate molecules, bebt-908 (PI3K / HDAC double target inhibitor, injection), bebt-906 (PI3K / HDAC double target inhibitor, oral) and bebt-201 (HDAC / BCR ABL / SFK multiple target inhibitor), and bebt-908 It is the most advanced project It is said that it has entered into clinical research in China Therefore, it is inferred that shuangtinita is bebt-908 Product name, target indication, manufacturer type rx108 Application of Suzhou Runxin biology for clinical application of ibuprofen cyclooxygenase inhibitor asthma Tianjin Xinchen taifeier applied for clinical bgb-283 B-Raf inhibitor tumor Baiji Shenzhou Application for clinical production of p-toluenesulfonamide lung cancer Application for clinical tpn171h PDE5 Clinical application of gemazazolam GABA receptor agonist Clinical application of PI3K / HDAC double target inhibitor for blood cancer Progress in research and development of biological products Qilu applied for chimeric anti EGFR monoclonal antibody, which is the fourth monoclonal antibody developed in Qilu Before that, human anti VEGF monoclonal antibody, all human anti TNF α monoclonal antibody and all human anti RANKL were also applied MAb Dongyao pharmaceutical declared tab008 monoclonal antibody, but no relevant information was found Shanghai Pharmaceutical Group declared humanized anti-CD20 monoclonal antibody, which can be used to treat non Hodgkin's lymphoma, chronic lymphoblastic leukemia and rheumatoid arthritis The first generation is rituximab, and now Roche has launched the second generation of obinutuzumab Shanghai Institute of biological products declared the split vaccine of influenza a h7n9 virus, which is the fourth h7n9 vaccine after Hualan biology, Tiantan biology and Kexing biology Baiaotai biological declared anti VEGF monoclonal antibody, which may be used to treat solid tumor or wet AMD Kangningjierui biological declared the recombinant human follicle stimulating hormone Fc fusion protein, and the internal code of kangningjierui company is kn-015 The drug is a fusion protein of FSH and FC, which prolongs the half-life of FSH It is used in the treatment of infertility and in vitro fertilization 3 Research and development progress of generic drugs (top 3) generic name indication: the original manufacturer classifies and imitates the domestic status of the manufacturer The first production report of Nippon Chemiphar 3 + 3 Dianhong Pharmaceutical Group Vomiting caused by chemotherapy with fosapitam: the second report of Merck 3 + 3 in Yichang humanwell Pharmaceutical Co., Ltd GlaxoSmithKline 3 + 3, the first report of chinda Tianqing Pharmaceutical Co., Ltd The third report of Chongqing Huabang pharmaceutical Dimethyl fumarate multiple sclerosis Biogen idea 3 + 3 the first report of Jiangsu Haosen Pharmaceutical Co., Ltd Kaglitazine type II diabetes J & J 3 + 3 the third report of Yangzi pharmaceutical industry Merck 3 + 3 the second clinical report of Chengdu Shengdi medicine Shio Nogi Inc 3 + 3 the first report of Nanjing Warwick Medical Co., Ltd clinical application of palipexone The third report of Qilu Pharmaceutical Co., Ltd on the production of pariprasidone schizophrenia J & J 3 + 6 the second report of Jingxin Pharmaceutical Co., Ltd in Zhejiang Province Astralas 3 + 3 the third report of Shandong chengchuang medicine Astralas 3 + 3 the second report of Sichuan Dikang Technology GlaxoSmithKline 3 + 3 the first report of Nanjing Huawei pharmaceutical clinical yidusaban